Unlocking the potential of
genomic medicine


Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary12/05/2019
PHILADELPHIA , Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. (" Cerecor ") (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an
Toggle Summary10/15/2019
PHILADELPHIA , Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the
Toggle Summary08/07/2019
Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase

Recent Presentations

More >>

Upcoming Events

More >>
There are currently no events to display.

Recent Events

More >>
Date Event Details
Summary Toggle 08/13/19 at 1:20 PM EDT

Aevi Genomic Medicine, Inc. at 2019 Wedbush PacGrow Healthcare Conference

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Data Provided by Refinitiv. Minimum 15 minutes delayed.